Clinical efficacy of Gamma Knife® combined with transarterial chemoembolization and immunotherapy in the treatment of primary liver cancer

Table 4 Incidence of adverse events, n (%)

	Incidence	Grade 3-5
Hypertension	10 (19.61)	4 (7.84)
Platelet reduction	14 (27.45)	2 (3.92)
ALT elevation	7 (13.73)	1 (1.96)
Leukocyte reduction	13 (25.49)	3 (5.88)
Nausea and vomiting	20 (39.22)	1 (1.96)
Fever	3 (5.88)	0 (0.00)
Hypothyroidism	2 (3.92)	0 (0.00)
Abdominal pain	4 (7.84)	0 (0.00)
Hyperbilirubinemia	6 (11.76)	0 (0.00)
Ascites	3 (5.88)	0 (0.00)
Hypokalemia	2 (3.92)	0 (0.00)